CN1778963A - Determination of blood ammonia content and blood ammonia diagnostic reagent kit - Google Patents
Determination of blood ammonia content and blood ammonia diagnostic reagent kit Download PDFInfo
- Publication number
- CN1778963A CN1778963A CN 200410065559 CN200410065559A CN1778963A CN 1778963 A CN1778963 A CN 1778963A CN 200410065559 CN200410065559 CN 200410065559 CN 200410065559 A CN200410065559 A CN 200410065559A CN 1778963 A CN1778963 A CN 1778963A
- Authority
- CN
- China
- Prior art keywords
- blood ammonia
- acid
- reagent
- glutamate
- content
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention is about a method of measuring the content of blood ammonia, and it also concerns the reagent box of blood ammonia diagnosis. This invention belongs to the field of medical testing and measuring technology. The reagent box is consisted of buffer solution, 2-ketoglutarate, reduced coenzyme, adenosine triphosphate, phosphoenolpyruvate, glutamate dehydrogenase, glutamate kinase, pyruvate kinase, lactate dehydrogenase and stabilizer. Firstly, we cause an enzyme-coupled reaction through mixing the sample and the reagent according to a certain proportion of volume; secondly, put the final reactant under the biochemical analyzer and test the absorbance variational situation (speed) of dominant wavelength; then we can get the content of blood ammonia. By using this invention, we can get the necessary measuring result with high sensitiveness and fine precision through biochemical analyzer, and the result would not be contaminated by material of internal and exogenous sources. Thus, this method can be conveniently promoted and applied.
Description
Technical field
The present invention relates to a kind of method of measuring blood ammonia content, the invention still further relates to the blood ammonia diagnostic kit simultaneously, belong to medical test determination techniques field.
Background technology
The ammonia measuring method has microdiffusion, ion exchange method, enzyme process and ammonia electrode method etc.Use at present maximum methods and be enzyme process and based on the determination of blood ammonia instrument analytical method of ion selective electrode.
Diffusion process discharges NH after being the sample alkalization
3, the ammonia that discharges with acidometric titration, or form the two mercury amine of pale brown look iodate with the Nessler reaction and carry out colorimetric.These methods need alkalization, and endogenic ammonia forms and impacts, and its accuracy and precision are affected, and seldom use at present; Ion exchange method is more accurate than diffusion process, and CV is 8%--13%; Ion selective electrode method is to utilize NH
3Be diffused into electrode surface, the PH that causes electrode changes and measures, and the CV of this method is 3.5%--4.8%, rate of recovery height, but all need special instrument, be not suitable for the concrete reality of China.
The retrieval Chinese patent is only found No. 87105593.7 patent applications and is disclosed a kind of rapid freezing cup for blood ammonia determination, does not but find more satisfactory determination of blood ammonia method.
Summary of the invention
The technical problem to be solved in the present invention is: propose a kind of blood ammonia Determination on content method that can overcome above prior art shortcoming, provide simultaneously in order to realize the blood ammonia diagnostic kit of the inventive method.Adopt the reagent in this test kit not only can measure, and finding speed is fast, accuracy is high, thereby can obtains practical applying at ultraviolet analyser or half, the enterprising promoting circulation of blood ammonia content of automatic clinical chemistry analyzer.
It is as follows that the present invention measures the method steps of blood ammonia content:
1), with sample and the reagent mix of mainly forming by 2-oxoglutaric acid ester, reduced coenzyme, adenosine triphosphate, phosphoenolpyruvic acid, glutamate dehydrogenase, Glutamate kinase, pyruvate kinase, serum lactic dehydrogenase, make it to take place the reaction of following principle:
Ammonium ion+2-oxoglutaric acid ester+reduced coenzyme
Glutamate dehydrogenase
L-glutamic acid+coenzyme+water
Adenosine triphosphate+L-glutamic acid
Glutamate kinaseAdenosine diphosphate (ADP)+
L-glutamic acid 5-phosphoric acid
Adenosine diphosphate (ADP)+phosphoenolpyruvic acid
Pyruvate kinase
Adenosine triphosphate+pyruvic acid
Pyruvic acid+reduced coenzyme
Serum lactic dehydrogenaseLactic acid+coenzyme
2), detect the end reaction thing in predominant wavelength 340nm absorbancy decline scope, calculate the content of blood ammonia.
Common step 2) the end reaction thing is placed under ultraviolet analyser or half, the automatic clinical chemistry analyzer device, detect the degree that predominant wavelength 340nm absorbancy descends, calculate the content of blood ammonia.
The blending ratio of above sample and reagent is by volume 1/10 to 1/250, and the mensuration temperature of above process is controlled at 20 ℃ to 50 ℃ conventional scopes, and the reaction times was controlled at conventional 2-30 minute.
This method is used glutamate dehydrogenase coupling Glutamate kinase, pyruvate kinase, lactic dehydrogenase enzyme reaction continuous monitoring method.Ammonia, 2-oxoglutaric acid ester and reduced coenzyme are by the effect of glutamate dehydrogenase, produce L-glutamic acid, L-glutamic acid generates ADP by Glutamate kinase catalysis and ATP, ADP produces pyruvic acid at last with phosphoenolpyruvic acid again under the effect of pyruvate kinase, effect by the coupling serum lactic dehydrogenase again, reduced coenzyme (absorption peak being arranged at the 340nm place) is oxidized into coenzyme (not having absorption peak at the 340nm place), thereby measured the speed that reduced coenzyme descends in 340nm place absorbancy, by measuring the speed that 340nm place absorbancy descends, can calculate the active size of adenosine deaminase.Advantage of the present invention is that reaction has utilized the reduced coenzyme of two molecules, has also produced the oxidized coenzyme of two molecules, so absorbancy has the duple pace of change, and sensitivity has also just improved two times.
Be used to realize that the blood ammonia diagnostic kit of the inventive method can be single agent, comprise:
Damping fluid 40--200mmol/l
2-oxoglutaric acid ester 1--50mmol/l
Reduced coenzyme 0.15--0.3mmo/l
Adenosine triphosphate 1--10mmol/l
Phosphoenolpyruvic acid 1--10mmol/l
Glutamate dehydrogenase 1000--50000U/l
Glutamate kinase 1000--50000U/l
Pyruvate kinase 500--20000U/l
Lactic dehydrogenase 10 00--50000U/l
Stablizer 10--80% (cumulative volume)
Also above single agent following pair of agent be can be made into, inside and outside source L-glutamic acid, adenosine diphosphate (ADP), pyruvic acid pollution more helped eliminating:
Reagent I
Damping fluid 40--200mmol/l
2-oxoglutaric acid ester 1--50mmol/l
Reduced coenzyme 0.15--0.3mmo/l
Adenosine triphosphate 1--10mmol/l
Phosphoenolpyruvic acid 1--10mmol/l
Glutamate kinase 1000--50000U/l
Pyruvate kinase 500--20000U/l
Lactic dehydrogenase 10 00--50000U/l
Stablizer 10--80% (cumulative volume)
Reagent II
Damping fluid 40--200mmol/l
Glutamate dehydrogenase 1000--50000U/l
Stablizer 10--80% (cumulative volume)
The prescription of two agent is not limited only to above-mentioned prescription, the composition of reagent I wherein, 2-oxoglutaric acid ester, reduced coenzyme, adenosine triphosphate, phosphoenolpyruvic acid, Glutamate kinase, pyruvate kinase, serum lactic dehydrogenase etc. can be placed on reagent II, reagent II composition wherein, glutamate dehydrogenase also can be placed on reagent I, so can form multiple formulations, not describe in detail one by one at this.
Reagent can also be made into following three reagent, not only more help eliminating inside and outside source L-glutamic acid, adenosine diphosphate (ADP), pyruvic acid pollution, also more help the stable of reagent:
Reagent I
Damping fluid 40--200mmol/l
2-oxoglutaric acid ester 1--50mmol/l
Reduced coenzyme 0.15--0.3mmo/l
Adenosine triphosphate 1--10mmol/l
Phosphoenolpyruvic acid 1--10mmol/l
Stablizer 10--50mmol/l
Reagent II
Damping fluid 40--200mmol/l
Glutamate kinase 1000--50000U/l
Pyruvate kinase 500--20000U/l
Lactic dehydrogenase 10 00--50000U/l
Stablizer 10--80% (cumulative volume)
Reagent III
Damping fluid 40--200mmol/l
Glutamate dehydrogenase 1000--50000U/l
Stablizer 10--80% (cumulative volume)
Three doses prescription is not limited only to above-mentioned prescription, the composition of reagent I wherein, and 2-oxoglutaric acid ester, reduced coenzyme, adenosine triphosphate, phosphoenolpyruvic acid etc. can be placed among reagent II or the reagent III.Reagent II composition wherein, Glutamate kinase, pyruvate kinase, serum lactic dehydrogenase etc. also can be placed among reagent I or the reagent III.Reagent III composition wherein, glutamate dehydrogenase also can be placed among reagent I or the reagent II, so can form multiple formulations, not at this detailed description.
The pH scope of buffer reagent can be 6.0～11.0.Buffer reagent can be three (carboxymethyl) aminomethane-hydrochloric acid (Tris-HCl) damping fluid, phosphoric acid salt (Phosphate) damping fluid, trolamine (Triethanolamine) damping fluid, 2-amino-2-methyl-1-propanol (2-Amino-2-methyl-1-propanol) damping fluid, imidazoles (Imidazole) damping fluid or glycylglycine (Glycylglyc ine) damping fluid etc., but being not limited only to these damping fluids, (for example can also be imidazoles/hydrochloride buffer 6.2-7.8; Sodium phosphate dibasic citrate buffer solution 5.0-8.0; Citric acid sodium citrate buffer solution 5.0-6.6; Phosphate buffered saline buffer 6.0-8.0; Sodium phosphate dibasic-potassium phosphate buffer 6.0-8.0; Potassium primary phosphate sodium hydrate buffer solution 6.0-8.0; Veronal sodium-hydrochloride buffer 6.8-9.6; Tris hydrochloride buffer 7.0-9.0; Boric acid borate buffer solution 7.4-9.0; Glycine-sodium hydrate buffer solution 8.6-10.6; Sand-sodium hydrate buffer solution 9.2-10:0; Yellow soda ash-sodium bicarbonate buffer liquid 8.8-10.6 (Ca
2+, Mg
2+Must not use when existing); PBS damping fluid 7.0-7.6 etc.).
Above reduced coenzyme can be reduced form nicotinamide coenzyme or derivatives thereofs such as NADPH, NADH or thio-NADH.
In addition, in order to reduce the cross influence between each reagent composition, the stability that keeps reagent, so that standing storage, above single agent, the reagent I of two agent, the reagent I of reagent II or three doses, reagent II, usually add stablizer 10～80% or 10～50mmol/l among the reagent III, stablizer can be an ethylene glycol, propylene glycol, glycerine, glycan, polyalcohols, in sulfuric acid amine or the salt etc. one or more can also be at thioglycol, adenosine diphosphate (ADP), bovine serum albumin, carbonate, cholate, dextran, ethylenediamine tetraacetic acid (EDTA), flavin adenine dinucleotide, vitamin B2 phosphate, glucose, glutaminate, lactose, N.F,USP MANNITOL, sucrose, sodium-chlor, select in the succinate etc.
Experiment shows, takes all factors into consideration from the accuracy of measurement result and economy two aspects of preparation cost, no matter is single agent, two agent or three doses, and the blood ammonia diagnostic kit of the present invention of following system component relation is comparatively desirable:
Damping fluid 80--120mmol/l
2-oxoglutaric acid ester 5--20mmol/l
Reduced coenzyme 0.2--0.3mmo/l
Adenosine triphosphate 2--8mmol/l
Phosphoenolpyruvic acid 2--8mmol/l
Glutamate dehydrogenase 5000--20000U/l
Glutamate kinase 5000--20000U/l
Pyruvate kinase 1000--10000U/l
Serum lactic dehydrogenase 5000--20000U/l
Stablizer 20--50% (cumulative volume)
Because the present invention utilizes Enzymology method, enzyme digestion reaction to have the high characteristics of specificity fully, is not vulnerable to the interference of other materials of inside and outside source.Easy, the easy handling of enzyme process method.The specificity of enzyme digestion reaction impels test result accurate.Enzyme digestion reaction all is to carry out under buffer conditions, does not have environmental pollution problem.The enzyme process method does not need special, extra instrument, and testing cost is cheap.Therefore can guarantee to have higher test accuracy, be more convenient for applying.
In addition, one of striking features of the present invention is the pollution that can eliminate inside and outside source L-glutamic acid, adenosine diphosphate (ADP), pyruvic acid, the effect of eliminating inside and outside source L-glutamic acid, adenosine diphosphate (ADP), pyruvic acid occurs in the first half of entire reaction time period, be consumed totally at time second half section contaminated inside and outside source L-glutamic acid, adenosine diphosphate (ADP), pyruvic acid, and all be the content that results from blood ammonia at the needed L-glutamic acid of second half section time test blood ammonia content, adenosine diphosphate (ADP), pyruvic acid.
Embodiment
The present invention is further illustrated below in conjunction with examples of implementation.
Embodiment one (single agent)
The blood ammonia diagnostic kit of present embodiment comprises:
Damping fluid 80mmol/l
2-oxoglutaric acid ester 5mmol/l
Reduced coenzyme 0.2mmo/l
Adenosine triphosphate 2mmol/l
Phosphoenolpyruvic acid 2mmol/l
Glutamate dehydrogenase 5000U/l
Glutamate kinase 5000U/l
Pyruvate kinase 1000U/l
Serum lactic dehydrogenase 5000U/l
Stablizer 50% (cumulative volume)
On automatic clinical chemistry analyzer, set: 37 ℃ of temperature, 10 minutes reaction times, test predominant wavelength 340nm, more than the test commplementary wave length 405nm, the volume ratio of tested blood ammonia sample and reagent is 1/25, the Direction of Reaction is negative reaction.
After adding sample and reagent, make it to mix, following reaction take place:
Ammonium ion+2-oxoglutaric acid ester+reduced coenzyme
Glutamate dehydrogenase
L-glutamic acid+coenzyme+water
Adenosine triphosphate+L-glutamic acid
Glutamate kinaseAdenosine diphosphate (ADP)+
L-glutamic acid 5-phosphoric acid
Adenosine diphosphate (ADP)+phosphoenolpyruvic acid
Pyruvate kinase
Adenosine triphosphate+pyruvic acid
Pyruvic acid+reduced coenzyme
Serum lactic dehydrogenaseLactic acid+coenzyme
The end reaction thing is placed under the biochemical analyzer, detect predominant wavelength 340nm absorbancy decline scope, thereby calculate the content of blood ammonia.
Present embodiment is used glutamate dehydrogenase coupling Glutamate kinase, pyruvate kinase, lactic dehydrogenase enzyme reaction continuous monitoring method.Ammonia, 2-oxoglutaric acid ester and reduced coenzyme are by the effect of glutamate dehydrogenase, produce L-glutamic acid, L-glutamic acid generates ADP by Glutamate kinase catalysis and ATP, ADP produces pyruvic acid at last with phosphoenolpyruvic acid again under the effect of pyruvate kinase, effect by the coupling serum lactic dehydrogenase again, reduced coenzyme (absorption peak being arranged at the 340nm place) is oxidized into coenzyme (not having absorption peak at the 340nm place), thereby measured the speed that reduced coenzyme descends in 340nm place absorbancy, by measuring the speed that 340nm place absorbancy descends, can calculate the active size of adenosine deaminase.
Embodiment two (two agent)
The blood ammonia diagnostic reagent of present embodiment has:
Reagent I
Damping fluid 100mmol/l
2-oxoglutaric acid ester 12mmol/l
Reduced coenzyme 0.25mmo/l
Adenosine triphosphate 5mmol/l
Phosphoenolpyruvic acid 5mmol/l
Glutamate kinase 12000U/l
Pyruvate kinase 6000U/l
Serum lactic dehydrogenase 12000U/l
Stablizer 50% (cumulative volume)
Reagent II
Damping fluid 100mmol/l
Glutamate dehydrogenase 12000U/l
Stablizer 50% (cumulative volume)
When measuring blood ammonia content, temperature is controlled at 30 ℃, 15 minutes reaction times, and test predominant wavelength 340nm, more than the test commplementary wave length 405nm, the volume ratio of tested blood ammonia sample and reagent is 1/25, the Direction of Reaction is negative reaction.
Concrete determination step is:
Ammonium ion+2-oxoglutaric acid ester+reduced coenzyme
Glutamate dehydrogenase
L-glutamic acid+coenzyme+water
Adenosine triphosphate+L-glutamic acid
Glutamate kinaseAdenosine diphosphate (ADP)+
L-glutamic acid 5-phosphoric acid
Adenosine diphosphate (ADP)+phosphoenolpyruvic acid
Pyruvate kinase
Adenosine triphosphate+pyruvic acid
Pyruvic acid+reduced coenzyme
Serum lactic dehydrogenaseLactic acid+coenzyme
The end reaction thing is placed under the biochemical analyzer, detect predominant wavelength 340nm absorbancy decline scope, thereby calculate the content of blood ammonia.
The reaction times of each reactions steps was controlled at 15 minutes.
Embodiment three (three doses)
The blood ammonia diagnostic reagent of present embodiment is three doses, has:
Reagent I
Damping fluid 120mmol/l
2-oxoglutaric acid ester 20mmol/l
Reduced coenzyme 0.3mmo/l
Adenosine triphosphate 8mmol/l
Phosphoenolpyruvic acid 8mmol/l
Stablizer 20mmol/l
Reagent II
Damping fluid 120mmol/l
Glutamate kinase 20000U/l
Pyruvate kinase 10000U/l
Serum lactic dehydrogenase 20000U/l
Stablizer 50% (cumulative volume)
Reagent III
Damping fluid 120mmol/l
Glutamate dehydrogenase 20000U/l
Stablizer 50% (cumulative volume)
On automatic clinical chemistry analyzer, set: 25 ℃ of temperature, 20 minutes reaction times, test predominant wavelength 340nm, more than the test commplementary wave length 405nm, the volume ratio of tested blood ammonia sample and reagent is 1/25, the Direction of Reaction is negative reaction.
Concrete determination step is:
Ammonium ion+2-oxoglutaric acid ester+reduced coenzyme
Glutamate dehydrogenase
L-glutamic acid+coenzyme+water
Adenosine triphosphate+L-glutamic acid
Glutamate kinaseAdenosine diphosphate (ADP)+
L-glutamic acid 5-phosphoric acid
Adenosine diphosphate (ADP)+phosphoenolpyruvic acid
Pyruvate kinase
Adenosine triphosphate+pyruvic acid
Pyruvic acid+reduced coenzyme
Serum lactic dehydrogenaseLactic acid+coenzyme
The end reaction thing is placed under the biochemical analyzer, detect predominant wavelength 340nm absorbancy decline scope, thereby calculate the content of blood ammonia.
The reaction times of each reactions steps was controlled at 20 minutes.
Embodiment four
The blood ammonia diagnostic reagent of present embodiment has:
Reagent I
Damping fluid 100mmol/l
2-oxoglutaric acid ester 8mmol/l
Reduced coenzyme 0.3mmo/l
Adenosine triphosphate 2mmol/l
Phosphoenolpyruvic acid 2mmol/l
Stablizer 20mmol/l
Reagent II
Damping fluid 100mmol/l
Glutamate dehydrogenase 10000U/l
Glutamate kinase 10000U/l
Pyruvate kinase 6000U/l
Serum lactic dehydrogenase 20000U/l
Stablizer 50% (cumulative volume)
On Biochemical Analyzer, set: 37 ℃ of temperature, 10 minutes reaction times, test predominant wavelength 340nm, more than the test commplementary wave length 405nm, the volume ratio of tested blood ammonia sample and reagent is 1/25, the Direction of Reaction is negative reaction.
After adding sample and reagent, make it to mix, following reaction take place:
Ammonium ion+2-oxoglutaric acid ester+reduced coenzyme
The L-glutamic acid deoxygenase
L-glutamic acid+coenzyme+water
Adenosine triphosphate+L-glutamic acid
Glutamate kinaseAdenosine diphosphate (ADP)+
L-glutamic acid 5-phosphoric acid
Adenosine diphosphate (ADP)+phosphoenolpyruvic acid
Pyruvate kinase
Adenosine triphosphate+pyruvic acid
Pyruvic acid+reduced coenzyme
Serum lactic dehydrogenaseLactic acid+coenzyme
The end reaction thing is placed under the biochemical analyzer, detect predominant wavelength 340nm absorbancy decline scope, thereby calculate the content of blood ammonia.
In a word, experiment showed, and adopt measuring method of the present invention can draw required measurement result by ultraviolet analyser or half, automatic clinical chemistry analyzer device fully, and highly sensitive, tolerance range good, is not subjected to the pollution of inside and outside source material.
Claims (9)
1. method of measuring blood ammonia content, step is as follows:
1), with sample and the reagent mix of mainly forming by 2-oxoglutaric acid ester, reduced coenzyme, adenosine triphosphate, phosphoenolpyruvic acid, glutamate dehydrogenase, Glutamate kinase, pyruvate kinase, serum lactic dehydrogenase, make it to take place the reaction of following principle:
Ammonium ion+2-oxoglutaric acid ester+reduced coenzyme
Glutamate dehydrogenase
L-glutamic acid+coenzyme+water
Adenosine triphosphate+L-glutamic acid
Glutamate kinaseAdenosine diphosphate (ADP)+
L-glutamic acid 5-phosphoric acid
Adenosine diphosphate (ADP)+phosphoenolpyruvic acid
Pyruvate kinase
Adenosine triphosphate+pyruvic acid
Pyruvic acid+reduced coenzyme
Serum lactic dehydrogenaseLactic acid+coenzyme
2), detect the end reaction thing in predominant wavelength 340nm absorbancy decline scope, calculate the content of blood ammonia.
2. according to the method for the described mensuration blood ammonia of claim 1 content, it is characterized in that: described step 2) for the end reaction thing being placed under ultraviolet analyser or half, the automatic clinical chemistry analyzer, detect the degree that predominant wavelength 340nm absorbancy descends, calculate the content of blood ammonia.
3, according to the method for claim 1 or 2 described mensuration blood ammonia content, it is characterized in that: temperature is controlled at 20 ℃ to 50 ℃ scopes, and the reaction times was controlled at 2-30 minute.
4, according to the method for claim 1 or 2 described mensuration blood ammonia content, it is characterized in that: the ratio control of sample and reagent is 1/10 to 1/250.
5. blood ammonia diagnostic kit is grouped into by following one-tenth:
Damping fluid 40--200mmol/l
2-oxoglutaric acid ester 1--50mmol/l
Reduced coenzyme 0.15--0.3mmo/l
Adenosine triphosphate 1--10mmol/l
Phosphoenolpyruvic acid 1--10mmol/l
Glutamate dehydrogenase 1000--50000U/l
Glutamate kinase 1000--50000U/l
Pyruvate kinase 500--20000U/l
Lactic dehydrogenase 10 00--50000U/l
Stablizer 10--80% (cumulative volume)
6. according to the described blood ammonia diagnostic kit of claim 5, it is characterized in that: described reagent is made into single agent, two agent or three doses.
7. according to claim 5 or 6 described blood ammonia diagnostic kits, it is characterized in that: described stablizer is at least a in ethylene glycol, propylene glycol, glycerine, glycan, polyalcohols, ammonium sulfate or the salt.
8. according to claim 5 or 6 described blood ammonia diagnostic kits, it is characterized in that: the pH scope of described buffer reagent is 6.0～11.0, and described buffer reagent is a kind of in three (carboxymethyl) aminomethane-hydrochloride buffer, phosphate buffered saline buffer, trolamine damping fluid, 2-amino-2-methyl-1-propanol damping fluid, imidazole buffer or the glycylglycine damping fluid.
9, according to claim 5 or 6 described blood ammonia diagnostic kits, it is characterized in that: described reduced coenzyme is a kind of in NADPH, NADH or the thio-NADH reduced form nicotinamide coenzyme or derivatives thereof.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410065559 CN1778963A (en) | 2004-11-23 | 2004-11-23 | Determination of blood ammonia content and blood ammonia diagnostic reagent kit |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410065559 CN1778963A (en) | 2004-11-23 | 2004-11-23 | Determination of blood ammonia content and blood ammonia diagnostic reagent kit |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1778963A true CN1778963A (en) | 2006-05-31 |
Family
ID=36769418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410065559 Pending CN1778963A (en) | 2004-11-23 | 2004-11-23 | Determination of blood ammonia content and blood ammonia diagnostic reagent kit |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1778963A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102994612A (en) * | 2012-12-24 | 2013-03-27 | 北京利德曼生化股份有限公司 | Liquid monomer reagent for determining content of ammonia in blood serum, preparation method and application thereof |
| CN104039358A (en) * | 2011-09-30 | 2014-09-10 | 海波龙治疗公司 | Methods of therapeutic monitoring of nitrogen scavenging drugs |
| CN104374906A (en) * | 2014-11-28 | 2015-02-25 | 山东博科生物产业有限公司 | Serum ammonia detection reagent |
| CN104797272A (en) * | 2012-11-21 | 2015-07-22 | 海波龙治疗公司 | Methods of administering and evaluating nitrogen scavenging drugs for the treatment of hepatic encephalopathy |
| CN105420344A (en) * | 2015-12-12 | 2016-03-23 | 山东博科生物产业有限公司 | Stable serum-potassium detection reagent with high anti-interference capability and detection method |
| CN106811505A (en) * | 2015-11-30 | 2017-06-09 | 山东博科生物产业有限公司 | A kind of strong single reagent liquid blood ammonia of stability（AMM）Detection reagent |
| US9914692B2 (en) | 2016-05-25 | 2018-03-13 | Horizon Therapeutics, Llc | Procedure for the preparation of 4-phenyl butyrate and uses thereof |
| US10668040B2 (en) | 2017-09-11 | 2020-06-02 | Horizon Therapeutics, Llc | Treatment of urea cycle disorders in neonates and infants |
-
2004
- 2004-11-23 CN CN 200410065559 patent/CN1778963A/en active Pending
Cited By (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10183005B2 (en) | 2011-09-30 | 2019-01-22 | Horizon Therapeutics, Llc | Methods of therapeutic monitoring of nitrogen scavenging drugs |
| US9962358B2 (en) | 2011-09-30 | 2018-05-08 | Horizon Therapeutics, Llc | Methods of therapeutic monitoring of nitrogen scavenging drugs |
| US10045958B1 (en) | 2011-09-30 | 2018-08-14 | Horizon Therapeutics, Llc | Methods of therapeutic monitoring of nitrogen scavenging drugs |
| US10183004B2 (en) | 2011-09-30 | 2019-01-22 | Horizon Therapeutics, Llc | Methods of therapeutic monitoring of nitrogen scavenging drugs |
| US10045959B1 (en) | 2011-09-30 | 2018-08-14 | Horizon Therapeutics, Llc | Methods of therapeutic monitoring of nitrogen scavenging drugs |
| US10617665B2 (en) | 2011-09-30 | 2020-04-14 | Horizon Therapeutics, Llc | Methods of therapeutic monitoring of nitrogen scavenging drugs |
| US10183002B2 (en) | 2011-09-30 | 2019-01-22 | Horizon Therapeutics, Llc | Methods of therapeutic monitoring of nitrogen scavenging drugs |
| US10183006B2 (en) | 2011-09-30 | 2019-01-22 | Horizon Therapeutics, Llc | Methods of therapeutic monitoring of nitrogen scavenging drugs |
| US10183003B2 (en) | 2011-09-30 | 2019-01-22 | Horizon Therapeutics, Llc | Methods of therapeutic monitoring of nitrogen scavenging drugs |
| US9999608B2 (en) | 2011-09-30 | 2018-06-19 | Horizon Therapeutics, Llc | Methods of therapeutic monitoring of nitrogen scavenging drugs |
| US9962359B2 (en) | 2011-09-30 | 2018-05-08 | Horizon Therapeutics, Llc | Methods of therapeutic monitoring of nitrogen scavenging drugs |
| CN104039358A (en) * | 2011-09-30 | 2014-09-10 | 海波龙治疗公司 | Methods of therapeutic monitoring of nitrogen scavenging drugs |
| CN104797272A (en) * | 2012-11-21 | 2015-07-22 | 海波龙治疗公司 | Methods of administering and evaluating nitrogen scavenging drugs for the treatment of hepatic encephalopathy |
| CN102994612A (en) * | 2012-12-24 | 2013-03-27 | 北京利德曼生化股份有限公司 | Liquid monomer reagent for determining content of ammonia in blood serum, preparation method and application thereof |
| CN104374906A (en) * | 2014-11-28 | 2015-02-25 | 山东博科生物产业有限公司 | Serum ammonia detection reagent |
| CN106811505A (en) * | 2015-11-30 | 2017-06-09 | 山东博科生物产业有限公司 | A kind of strong single reagent liquid blood ammonia of stability（AMM）Detection reagent |
| CN106811505B (en) * | 2015-11-30 | 2020-11-24 | 山东博科生物产业有限公司 | Single-reagent liquid ammonia blood (AMM) detection reagent with strong stability |
| CN105420344A (en) * | 2015-12-12 | 2016-03-23 | 山东博科生物产业有限公司 | Stable serum-potassium detection reagent with high anti-interference capability and detection method |
| US11014870B2 (en) | 2016-05-25 | 2021-05-25 | Horizon Therapeutics, Llc | Procedure for the preparation of 4-phenyl butyrate and uses thereof |
| US9914692B2 (en) | 2016-05-25 | 2018-03-13 | Horizon Therapeutics, Llc | Procedure for the preparation of 4-phenyl butyrate and uses thereof |
| US10329236B2 (en) | 2016-05-25 | 2019-06-25 | Horizon Therapeutics, Llc | Procedure for the preparation of 4-phenyl butyrate and uses thereof |
| US10668040B2 (en) | 2017-09-11 | 2020-06-02 | Horizon Therapeutics, Llc | Treatment of urea cycle disorders in neonates and infants |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1769481A (en) | Blood ammonia content determination method and blood ammonia diagnosis kit | |
| CN1749756A (en) | Method for detecting blood ammonia content and blood ammonia diagnostic reagent kit | |
| CN1778963A (en) | Determination of blood ammonia content and blood ammonia diagnostic reagent kit | |
| CN1778944A (en) | Determination of creatinine content and creatinine diagnostic reagent kit | |
| CN1778946A (en) | Determination of blood ammonia content and blood ammonia diagnostic reagent kit | |
| CN1778947A (en) | Creatinine content determination and creatinine diagnostic reagent kit | |
| CN1778945A (en) | Determination of blood ammonia content and blood ammonia diagnostic reagent kit | |
| CN1778937A (en) | Determination of blood ammonia content and blood ammonia diagnostic reagent kit | |
| CN1746316A (en) | Determination of adenosine deaminase activity and diagnostic kit of adenosine deaminase | |
| CN1778964A (en) | Determination of 5'-nucleotidase activity and its diagnostic reagent kit of 5'-nucleotidase | |
| CN1749754A (en) | Method for detecting blood ammonia content and blood ammonia diagnostic reagent kit | |
| CN1749411A (en) | Method for measuring 5'-nucleotidase activity and diagnostic kit of 5'-nucleotidase | |
| CN1778965A (en) | Determination of 5'-nucleotidase acitivity and its diagnostic reagent kit of 5'-nucleotidase | |
| CN1769478A (en) | Adenosine deaminase activity determination method and adenosine deaminase diagnosi kit | |
| CN1757748A (en) | Determination method of creatnine content and creatnine diagnosis reagent box | |
| CN1757754A (en) | Determination method of creatnine content and reagent box for diagnosing creatnine | |
| CN1769475A (en) | Adenosine deaminase activity determination method and adenosine deaminase diagnosi kit | |
| CN1769482A (en) | Adenosine deaminase activity determination method and adenosine deaminase diagnosi kit | |
| CN1757750A (en) | Method of determining creatnine content and reagent box for diagnosing creatnine | |
| CN1769479A (en) | Adenosine deaminase activity determination method and adenosine deaminase diagnosi kit | |
| CN1746678A (en) | Method and kit for measuring ammonia in blood | |
| CN1757749A (en) | Determination method of creatnine content and creatnine oiagnosis reagent box | |
| CN1749405A (en) | Method for measuring 5'-nucleotidase activity and Diagnostic reagent kit of 5'-nucleotidase | |
| CN1769484A (en) | Adenosine deaminase activity determination method and adenosine deaminase diagnosi kit | |
| CN1769477A (en) | Adenosine deaminase activity determination method and adenosine deaminase diagnosi kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |